NAD+ decides whether a healing macrophage also turns fibrotic
While the metabolic cofactor NAD+ is plentiful, the enzyme SIRT6 holds the TGFB1 promoter closed and a macrophage can resolve inflammation without driving scar. Aged macrophages lose most of their NAD+, the brake comes off, and restoring it should put the brake back.
Omega Point 1.0
Stage of verification
- Hypothesis published2026-09-14
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Lens
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

Metabolite or ion
NAD+
A molecule whose availability supports SIRT6 activity and contributes to the mitochondrial NAD+/NADH ratio
Where this hypothesis actsAged human macrophages with depleted NAD+ undergoing SPM-driven M2 polarization
Hypotheses on this target 1
Supplementation1
Accelerated excretion
Composition restoration

What is proposed
Supplementation
Increase NAD+ availability
With whatSmall molecule
HowReplete NAD+ using NMN or NR; the proposed test uses NMN at 1 mM for 48 hours before SPM-driven M2 polarization
Possible result
Expected restoration of TGFB1 silencing and reduced TGF-β1 secretion during M2 polarization
From the recordNAD+ repletion (NMN/NR) in aged human macrophages should restore SIRT6-mediated TGFB1 silencing during SPM-driven M2 polarization.

Enzyme
SIRT6
An enzyme that mediates deacetylation of the histone mark H3K9ac at the TGFB1 promoter
Where this hypothesis actsAged human macrophages with insufficient SIRT6 activity during SPM-driven M2 polarization
Hypotheses on this target 1
Inhibition
Activation1
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression
Function preservation

What is proposed
Activation
Restore SIRT6-mediated histone deacetylation
With whatSmall molecule
HowRestore activity through NAD+ repletion with NMN or NR; test dependence on SIRT6 using the inhibitor OSS_128167
Possible result
Expected TGFB1 silencing while SPM-driven IL-10/Arg1 upregulation proceeds
From the recordNAD+ repletion (NMN/NR) in aged human macrophages should restore SIRT6-mediated TGFB1 silencing during SPM-driven M2 polarization.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Helping old tissue repair itself may require separating signals that settle inflammation from signals that encourage scarring. The unexpected move is to propose that a cell's metabolic state controls a chemical lock on the gene producing a scarring signal. This is a hypothesis generated by the pipeline, not a measured result.
- Inflammation-resolving signals push macrophages toward a repair-associated state.
- In the proposed young-cell state, plentiful NAD+ supports SIRT6 activity.
- SIRT6 removes an acetyl mark from the DNA-packaging protein at the TGFB1 control region.
- That restraint keeps the scarring-signal gene available but silent while other repair-associated signals rise.
- In the proposed aged-cell state, depleted NAD+ weakens the restraint: the gene changes from available but silent to accessible to activating proteins.
- The repair-associated response can then also increase the scarring signal.
- Replenishing NAD+ is predicted to restore the restraint and separate the repair-associated response from scarring-signal release.
A repair crew shares a building with a concrete dispenser. The proposal puts a separately powered lock on the dispenser, so the crew can work without automatically pouring concrete; when that power runs low, the lock stops holding.
Where the picture breaks: Gene regulation is not a single mechanical lock, and releasing TGF-β1 does not itself establish that nearby tissue will form scar tissue. The picture also does not explain how a metabolic change in one cell compartment controls an enzyme acting on genetic material elsewhere.
- Master questionstep 01 of 04
Stem cell niches—the local surroundings that support cells capable of renewing tissue—are the target for rejuvenation.
Rests on: The goal is to restore a more youthful supporting environment for stem cells.
AssumptionThe goal assumes that these surroundings can be rejuvenated; the supplied question does not define what restored function would count as rejuvenation.
- Goal pillarstep 02 of 04
Weakening a self-reinforcing cycle between tissue mechanics, meaning physical forces and stiffness, and inflammation is selected as a route toward rejuvenation.
Rests on: This requires such a cycle to contribute to deterioration of the stem cell environment and its weakening to help restore that environment.
LeapThe preceding question supplies the goal but no account of this cycle or evidence that weakening it rejuvenates the niche. The supplied source excerpts do not establish that connection.
- Gap questionstep 03 of 04
Human niche macrophages—immune cells living in the stem cell environment—might release more or less transforming growth factor beta 1, or TGF-β1, a signal associated here with scarring, when specialized pro-resolving mediators, or SPMs, signals that help inflammation end, push them toward an M2 repair-associated state. The question takes as given that humans lack a protective chemical marking described in Acomys, the spiny mouse: DNA methylation, the addition of chemical marks to genetic material, at part of a binding site for interferon regulatory factor 4, or IRF4, a protein that regulates gene activity. It treats that marking as separating inflammation resolution from fibrosis, the accumulation of scar tissue.
Rests on: The preceding pillar supplies the aim of weakening the mechanics–inflammation cycle; this question selects the possibility that inflammation-resolving treatment also promotes scarring.
AssumptionThe Acomys marking, its protective role, and its absence in humans are premises of the question, not findings established by the supplied excerpts. The chain also assumes that this macrophage output matters to the selected tissue-level cycle.
- Hypothesisstep 04 of 04
A metabolic difference between young and aged macrophages is proposed to determine whether a repair-associated response also releases TGF-β1. The proposed controller is the ratio of nicotinamide adenine dinucleotide in its oxidized and reduced forms, NAD+ and NADH, within mitochondria, the cell's energy-processing compartments. The proposed route runs through sirtuin 6, or SIRT6, an enzyme that uses NAD+ to remove chemical groups from proteins. It would remove an acetyl chemical mark from lysine 9 of histone H3, a DNA-packaging protein, at the TGFB1 promoter, the control region of the gene encoding TGF-β1. This is proposed to keep that gene available but silent in young cells while other repair-associated signals increase; depleted NAD+ in aged cells would release this restraint. The Acomys DNA marking is proposed as a parallel way to restrain the same gene. The distinguishing prediction is that nicotinamide mononucleotide, or NMN, a substance used to replenish NAD+, given at 1 millimolar for 48 hours before the repair-associated response, will reduce TGF-β1 secretion by more than 50% relative to the treatment vehicle. The proposal predicts that OSS_128167, the specified SIRT6 inhibitor, will abolish this reduction and that the promoter's acetyl marking will fall.
Rests on: The preceding gap supplies the unresolved separation between inflammation resolution and scarring, together with a proposed gene-regulation precedent in Acomys. The endpoint offers a different chemical restraint as its proposed explanation in humans.
Stated in the chain
What is carried, and what is not. Two background relationships have explicit support in the supplied excerpts: S5, a 2022 Journal of Biological Chemistry mouse-macrophage study, describes the NAD+ dependence of the enzyme family containing SIRT6, without establishing the proposed human mechanism; S6, a 2023 Cells article, describes SIRT6 removing the relevant histone mark at other genes, not at TGFB1. Neither establishes these links in the proposed setting or the sequence end to end, and the endpoint's claimed 50–70% age-related NAD+ reduction is not substantiated by the supplied excerpts.S5S6
Where the reasoning is carried by something unstated · 3
- Master question. The goal assumes that these surroundings can be rejuvenated; the supplied question does not define what restored function would count as rejuvenation.
- Goal pillar. The preceding question supplies the goal but no account of this cycle or evidence that weakening it rejuvenates the niche. The supplied source excerpts do not establish that connection. Establish the missing link before relying on this step.
- Gap question. The Acomys marking, its protective role, and its absence in humans are premises of the question, not findings established by the supplied excerpts. The chain also assumes that this macrophage output matters to the selected tissue-level cycle.
How a result here could mislead · 3
- Lower TGF-β1 after NMN could reflect fewer surviving macrophages or failure to enter the repair-associated state, rather than selective silencing of the scarring-signal gene. What closes it: The comparison must measure surviving cell numbers and the proposal's other repair-associated signals alongside TGF-β1. Otherwise, selective separation of the two outputs remains unestablished.
- An NMN effect reversed by the specified inhibitor could be credited to the entire proposed route even though the mitochondrial ratio and SIRT6's action at this gene were never established. Conversely, a negative result could reflect failure to restore the proposed metabolic state. What closes it: The test must verify the mitochondrial NAD+/NADH change, SIRT6 activity, and loss of the acetyl mark at the TGFB1 control region. It also needs confirmation that the inhibitor's reversal depends on SIRT6; the supplied design does not establish that specificity.
- A change in released TGF-β1 in cultured macrophages could be read as proof of a change in tissue scarring. Rival explanations instead place control in culture-surface stiffness or in whether surrounding material lets the released signal act on neighboring cells. What closes it: Culture-surface stiffness must be controlled, and released TGF-β1 must be distinguished from its ability to activate neighboring scar-producing cells in the relevant surroundings. The supplied test specifies neither comparison.
What would make this wrong. The central chain would fail if verified restoration of the proposed mitochondrial NAD+/NADH state in aged human macrophages did not produce SIRT6-dependent loss of the acetyl mark at TGFB1 and reduced TGF-β1 release while the repair-associated response remained intact. A reduction that persisted despite verified loss of SIRT6 activity would contradict the claimed requirement for that enzyme.
What it would change. If the mechanism held, restoring the stem cell environment would require attention to whether a macrophage's metabolic state lets inflammation-resolving signals also trigger scarring signals. Ending inflammation alone would not establish that the repair response had been separated from that output. Even a successful test in aged human macrophages would leave tissue rejuvenation, lasting effects, and the proposed Acomys comparison unestablished.
Sources read · 10
Spatial and phenotypic heterogeneity of resident and monocyte-derived macrophages during inflammatory exacerbations leading to pulmonary fibrosis. · Frontiers in immunology · 2024
“To spatially define the phenotype of macrophages involved in fibrotic lung injury, fluorescent antibodies recognizing DNA (green), CD45 (yellow) and CD68 (red) were used to perform bulk sequencing in the injured/remodeled or peri-injured alveolar regions of the lung 14 days post SP-C I73T injury.”
Does not settle: This source text does not establish mitochondrial NAD+/NADH levels, SIRT6 activity, H3K9 acetylation at the TGFB1 promoter, SPM-driven M2 polarization, TGFB1 output, aging effects, human macrophage findings, or effects of NMN/NR.
Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. · Nature metabolism · 2022
“Here, we show that AC-derived methionine regulates resolution through epigenetic repression of the ERK1/2 phosphatase Dusp4.”
Does not settle: This source does not establish mitochondrial NAD+/NADH control, SIRT6, H3K9ac at the TGFB1 promoter, SPM-driven M2 polarization, aging-associated NAD+ reduction, Acomys methylation, or NMN/NR effects.
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression. · JHEP reports : innovation in hepatology · 2022
“Macrophages, one of the most widely studied immune cell populations in liver fibrosis, regulate both the progression and regression of liver fibrosis.”
Does not settle: This source does not establish effects of mitochondrial NAD+/NADH, SIRT6, H3K9ac at the TGFB1 promoter, SPM-driven M2 polarization, aging, NMN/NR, IRF4/STAT6, or Acomys methylation on TGFB1 expression.
The Role of MCPIP1 in Macrophage Polarization and Cardiac Function Post-Myocardial Infarction. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
“MCPIP1 suppresses the P53/ferroptosis pathway to regulate macrophage polarization and TGF‐β/SMAD3‐mediated fibroblast activation.”
Does not settle: It does not establish SPM-polarized human macrophage TGFB1 regulation by mitochondrial NAD+/NADH, SIRT6, H3K9ac, IRF4/STAT6, aging, Acomys methylation, or NMN/NR repletion.
SIRT6 stabilization and cytoplasmic localization in macrophages regulates acute and chronic inflammation in mice. · The Journal of biological chemistry · 2022
“Sirtuins (SIRTs) are NAD + -dependent deacylases that display key regulatory functions in metabolism regulation, cancer, aging, and inflammation”
Does not settle: This mouse macrophage study does not establish mitochondrial NAD+/NADH control of SIRT6, TGFB1 promoter H3K9 acetylation, SPM/M2 polarization, aging-related NAD+ reduction, or NMN/NR effects in human macrophages.
Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health. · Cells · 2023
“SIRT6 interacts with and suppresses Jun proto-oncogene (c-JUN) at the promoter regions of the IL6 and CCL2 genes. At the same time, SIRT6 also deacetylates H3K9 in the promoter chromatin of those target genes [ ].”
Does not settle: This source does not establish mitochondrial NAD+/NADH control of SIRT6, TGFB1 promoter regulation, SPM-polarized human macrophages, aging-related NAD+ reduction, TGF-β1 co-expression during M2 polarization, Acomys methylation, or effects of NMN/NR.
Efferocytosis by Macrophages Attenuates Inflammatory Responses Following Ultraviolet B-Induced Apoptosis in Corneal Stromal Cells. · Investigative ophthalmology & visual science · 2025
“Microenvironmental M1 macrophages exhibited reduced IL-1β, increased transforming growth factor beta 1, and downregulation of CD14, CD68, CD80, and CD11c.”
Does not settle: This source does not assess SPM polarization, human primary or aged macrophages, mitochondrial NAD+/NADH, SIRT6, H3K9ac or TGFB1-promoter regulation, Acomys methylation, or NMN/NR repletion.
Thrombospondin-1-mediated macrophage efferocytosis dysfunction exacerbates intestinal pathology in Hirschsprung's disease. · International immunopharmacology · 2026
“HSCR macrophages exhibited proinflammatory hyperactivation and impaired pro-resolving polarization with reduction of CD206+ proportion and downregulation of TGFB1.”
Does not settle: This source does not assess SPM polarization, mitochondrial NAD+/NADH, SIRT6, H3K9ac at the TGFB1 promoter, aging, NMN/NR treatment, IL-10/Arg1 co-expression, IRF4/STAT6, or Acomys DNA methylation.
Maresin 1 activates LGR6 signaling to inhibit smooth muscle cell activation and attenuate murine abdominal aortic aneurysm formation. · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
“Our findings provide a previously undescribed mechanistic pathway wherein ingestion of apoptotic SMCs by MaR1/LGR6 activated macrophages stimulate TGF-β signaling that protects SMC activation and MMP2-mediated vascular remodeling.”
Does not settle: This murine abdominal-aortic-aneurysm study does not establish TGFB1 output in SPM-polarized human macrophages, mitochondrial NAD+/NADH control, SIRT6 or H3K9ac regulation at the TGFB1 promoter, aging-related NAD+ reduction, Acomys methylation, or effects of NMN/NR.
A regulatory loop involving the cytochrome P450-soluble epoxide hydrolase axis and TGF-β signaling. · iScience · 2024
“The repolarization of M1 macrophages to M2c using TGF-β1 was associated with a significant decrease in Arg1 , Vtcn1 , and Snai1 expression.”
Does not settle: This source does not establish NAD+/NADH-dependent control of TGFB1, SIRT6 or H3K9ac at the TGFB1 promoter, SPM-driven polarization, aging-related NAD+ depletion, Acomys methylation, or effects of NMN/NR in human macrophages.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Do resolution signals make human repair macrophages release more of the scarring protein, or less?
Original wording · exactly as the pipeline generated it
Does SPM-driven M2 polarization in human niche macrophages increase or decrease TGF-β1 secretion, given that the Acomys IRF4-half-site CpG methylation decoupling pro-resolution from fibrosis is absent in humans?
What this question is asking
The question asks whether signals that help inflammation end also increase or decrease a protein that can promote scarring. Specifically, it asks whether specialized pro-resolving mediators (SPMs) push macrophages in the human stem cell niche toward an M2 repair-associated state and change their release of transforming growth factor beta 1 (TGF-β1), compared with otherwise comparable cells without that treatment. Its premise is that African spiny mice have a chemical mark at an interferon regulatory factor 4 (IRF4) half-site that separates inflammation resolution from scarring, and that humans lack this arrangement; the supplied sources do not establish that premise. The desired outcome is clearance of debris associated with senescent cells without activating scar-producing fibroblasts.
- Macrophage
- An immune cell that takes up cells and debris and releases signals that affect surrounding tissue. Its cleanup and signaling activities are the two functions being compared here.
- Inflammation resolution and specialized pro-resolving mediators (SPMs)
- Resolution is the process through which inflammation subsides. Specialized pro-resolving mediators are a class of signaling molecules associated with that process; the question asks whether their effects on cleanup also change a scar-promoting signal.
- M1, M2, polarization, and differentiation
- M1 and M2 are conventional labels for broadly inflammation-associated and repair-associated macrophage states. Polarization and differentiation describe shifts in cell characteristics; these labels summarize varied states rather than two fixed types, and M2 does not itself mean scar-free repair.
- Stem cell niche
- The local cells, signals, and physical surroundings that support stem cells, which can produce replacement cells. The question concerns macrophages in that environment, but the supplied input does not identify a particular human tissue niche.
- Transforming growth factor beta 1 (TGF-β1) and TGFB1
- TGF-β1 is a signaling protein described here in both inflammation-reducing and scar-promoting roles. TGFB1 names the gene encoding it; a change in gene expression does not by itself establish a change in protein release.
- Gene expression and protein secretion
- Gene expression is the use of genetic instructions to produce a cell's products. Secretion is release of a substance from the cell; the question asks about secretion, while S2 and S4 report expression of the gene encoding the protein.
- Fibroblast, fibroblast activation, fibrosis, and collagen
- Fibroblasts are cells that produce material supporting tissue, including the structural protein collagen. Activation can increase this activity, while fibrosis means excessive buildup of scar-like material; collagen uptake is removal into cells, not a direct measurement of scar formation.
- Senescent cells and aged red blood cells
- In the proposed niche problem, senescent cells are cells in a lasting state of no longer dividing. S7 concerns aged red blood cells, which carry oxygen; the supplied material does not establish that clearing them represents clearance of the senescent cells intended by the gap.
- Efferocytosis
- The process by which cells such as macrophages take up and clear dying cells. The sources use it for cleanup outcomes, which must be distinguished from measurements of released signaling proteins.
- Acomys
- The genus of African spiny mice named in the question. The proposed mechanism in these animals and its claimed absence in humans are premises under audit, not findings established by the supplied sources.
- Interferon regulatory factor 4 (IRF4) and half-site
- IRF4 is a protein that regulates gene activity by participating in binding to genetic material. A half-site is part of a larger binding pattern; the input proposes a mechanism involving such a site but supplies no establishing evidence.
- CpG methylation
- CpG denotes a cytosine followed by a guanine in deoxyribonucleic acid, the material carrying genetic instructions; the letter p represents the connecting phosphate. Methylation is addition of a chemical mark at such a site, proposed here to alter the relationship between inflammation resolution and scarring.
- Co-binding
- Binding involving more than one participant at a site or target. The gap description uses this term for IRF4 and TGF-β1 without specifying the participants' roles or binding target, so its precise meaning is not established here.
- Human monocyte-derived macrophages
- Macrophages developed from human monocytes, a type of blood immune cell. Findings in these cells do not by themselves establish the same response in macrophages within a stem cell niche.
- Corneal fibroblasts, ultraviolet B, and physical separation
- Corneal fibroblasts are support-producing cells from the eye's clear front surface. S2 uses ultraviolet B light to injure these cells and a compartment-separated laboratory setup involving macrophages; this is a different setting from the human niche specified in the question.
- Itaconate
- A molecule produced through cellular chemical processing. S4 links its late production to resolution-associated macrophage changes, but does not test the specialized pro-resolving mediator intervention asked about.
- Matrix metalloproteinase 8
- An enzyme involved in breaking down material surrounding cells. S4 reports its reduction alongside other changes, without establishing the requested TGF-β1 secretion outcome.
- 17R-resolvin D2
- The particular resolution-promoting signaling molecule studied in S7. Its reported effects on macrophage state and cell clearance provide nearby evidence, but not the requested measurement of TGF-β1 release.
- Glutamine metabolism
- The chemical processing of glutamine, a molecule cells use as a nutrient and building material. S5 connects that processing to M2 polarization without establishing the secretion response in the question.
Acomys IRF4-half-site CpG methylation decouples pro-resolution from fibrosis, and this decoupling mechanism is absent in humans.
The assumption concerns African spiny mice, a proposed short genetic binding site for a protein that regulates gene activity, and a chemical mark at that site. It claims that the mark lets inflammation subside without triggering scarring in these mice, while humans lack that separation. If established, this would supply a species-specific reason to question whether repair signals have the same scarring consequences in humans.
The supplied search results do not return work establishing either the proposed mouse mechanism or its absence in humans. S2 and S4 report changes in gene expression in other settings, S7 reports repair-associated and clearance effects of a resolution signal, and S5 and S9 concern other aspects of macrophage activity. None establishes the asserted species difference; this bounded set of sources does not show that the premise is false.S2S4S5S7S9
The same question asked without the part nothing read establishes:
- Does treatment with specialized pro-resolving mediators increase or decrease TGF-β1 release as macrophages in the human stem cell niche adopt an M2 repair-associated state?
- In macrophages in the human stem cell niche, does treatment with specialized pro-resolving mediators support debris clearance without increasing TGF-β1 release or fibroblast activation?
- TGF-β1 release increases Under the question's proposed mechanism, a treatment that promotes debris clearance would also increase a signal capable of activating fibroblasts. Clearance and scar-promoting activity could therefore rise together, so the repair-associated cell state would not by itself establish the desired separation.
- TGF-β1 release decreases If debris clearance also improved, the treatment would combine greater removal of unwanted material with less release of this scar-promoting signal. That would fit the requested separation at the level of these two measurements, but would not by itself establish reduced tissue scarring.
- No consistent direction If release remained unchanged or differed across conditions, the M2 label would not identify a consistent change in this signal. Any improvement in clearance would then leave the proposed effect on fibroblast activation unresolved.
The proposed chain starts with a signal changing the activity of tissue-cleaning immune cells. Those cells would need to remove debris while avoiding release of enough scar-promoting signals to activate fibroblasts. If the same treatment increased TGF-β1 release, interpreting a repair-associated cell state as evidence of scar-free repair could be mistaken. If it decreased release, assuming that repair-associated activity necessarily increases this scarring signal could also be mistaken. Neither direction alone would establish restoration of the environment that supports stem cells.
Two S-nodes predict opposite TGF-β1 outcomes from the same SPM intervention in human macrophages.
Macrophage polarization state that clears senescent debris without TGF-β1-driven fibroblast activation.
No human niche macrophage data on IRF4-TGF-β1 co-binding status during SPM-driven polarization; intervention direction is indeterminate.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
The TGF-β1 output of SPM-polarized human macrophages is controlled by mitochondrial NAD+/NADH ratio acting through SIRT6-mediated deacetylation of H3K9ac at the TGFB1 promoter. In young macrophages with high NAD+, SIRT6 maintains TGFB1 in a poised-but-silenced state during M2 polarization — SPM-driven IL-10/Arg1 upregulation proceeds without TGF-β1 co-expression. In aged macrophages with depleted NAD+ (documented50-70%reduction), SIRT6 activity is insufficient, H3K9 remains acetylated at TGFB1, and any transcriptional activator (including IRF4/STAT6 from M2 polarization) gains access. The IRF4 half-site methylation in Acomys is a parallel solution to the same problem — Acomys bypasses the NAD+ requirement by using DNA methylation instead of histone deacetylation to gate TGFB1. NAD+ repletion (NMN/NR) in aged human macrophages should restore SIRT6-mediated TGFB1 silencing during SPM-driven M2 polarization.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Pre-treatment of aged human macrophages with NMN (1mM,48h) before SPM-driven M2 polarization will reduce TGF-β1 secretion by >50%compared to vehicle, and this effect will be abolished by SIRT6 inhibitor OSS_128167. ChIP-qPCR will show restored H3K9 deacetylation at the TGFB1 promoter in NMN-treated aged macrophages.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies a quantitative secretion reduction, its abolition by an inhibitor, and a chromatin modification outcome. No rival prediction is supplied. A paper already fetched for this hypothesis bears on it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
NMN treatment of primary macrophages + ELISA + ChIP-qPCR all established protocols.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Pre-treatment of aged human macrophages with NMN (1mM, 48h) before SPM-driven M2 polarization will reduce TGF-β1 secretion by >50% compared to vehicle, and this effect will be abolished by SIRT6 inhibitor OSS_128167. ChIP-qPCR will show restored H3K9 deacetylation at the TGFB1 promoter in NMN-treated aged macrophages.
- What would separate them
Ageing installs the anti-fibrotic switch that spiny mice are born with predicts: Bisulfite sequencing of the IRF4 half-site CpG at the TGFB1 enhancer in FACS-sorted CD163+ niche macrophages will show >60% methylation in aged (65-75) human donors but <10% in young (20-30) donors, and this methylation will correlate inversely with TGF-β1 secretion upon SPM stimulation in ex vivo polarization assays.
- What would separate them
The fibrosis signal is stopped by the hyaluronan mesh, not by the macrophage predicts: In human niche explant co-cultures, adding exogenous ultra-HMW-HA (>6 MDa) to the macrophage-fibroblast interface will block TGF-β1-driven αSMA expression in fibroblasts even when macrophages are maximally M2-polarized with high TGF-β1 secretion, while low-MW HA (<500 kDa) will permit fibroblast activation at the same TGF-β1 concentration.
- Rival 03 of 04What would separate them
The link between resolving inflammation and fibrosis is an artefact of culture plastic predicts: Human monocyte-derived macrophages polarized with resolvin D1 on 2 kPa polyacrylamide gels will show <2-fold TGF-β1 increase vs. unpolarized controls, while the same cells on tissue culture plastic show >5-fold increase. YAP nuclear/cytoplasmic ratio will correlate with TGF-β1 output (r>0.7) across substrate stiffnesses.
- What would separate them
Resolvins may drive fibrosis in aged cells rather than resolve it predicts: In aged human macrophages with documented low FPR2 surface density, resolvin D1 treatment will increase TGF-β1 secretion above untreated controls (not just fail to decrease it), and this increase will be blocked by β-arrestin-2 siRNA but not by pertussis toxin (Gαi inhibitor), confirming β-arrestin-biased signaling as the driver.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
4 quantitative figures appear below and the hypothesis cites no study for any of them. They are the engine's own, and the marks in the text say which.
What it would take to refute it. 2 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: Abstract Book for the 27th Congress of the European Hematology Association; Ferroptosis and macrophage efferocytosis in periodontitis: Biological insights and therapeutic advances..
4 papers retrieved around this hypothesis
- Ferroptosis and macrophage efferocytosis in periodontitis: Biological insights and therapeutic advances.PMID 41091737 · full_text · 117,816 characters stored
- Posterseuropepmc:PMC:PMC11208286 · full_text · 1,026 characters stored
- Abstract Book for the 27th Congress of the European Hematology Associationeuropepmc:PMC:PMC9429973 · full_text · 8,794,916 characters stored
- Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>.PMID 33634751 · full_text · 322,070 characters stored
0 citation handles extracted; 1 Europe PMC search run; 4 records examined; 4 sources stored for enrichment, 4 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.